These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15577427)

  • 1. A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy.
    Antoniou T; Park-Wyllie L; Boyle E
    J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1666-7. PubMed ID: 15577427
    [No Abstract]   [Full Text] [Related]  

  • 2. [Darunavir in treatment-naïve patients. The ARTEMIS study].
    Estrada V; Fuster M
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():10-3. PubMed ID: 19195454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.
    Mole L; Schmidgall D; Holodniy M
    J Acquir Immune Defic Syndr; 2001 Jul; 27(3):260-5. PubMed ID: 11464145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients.
    Casau NC; Glesby MJ; Paul S; Gulick RM
    J Acquir Immune Defic Syndr; 2003 Apr; 32(5):494-8. PubMed ID: 12679700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.
    Bongiovanni M; Bini T; Chiesa E; Cicconi P; Adorni F; Monforte d'Arminio A
    Antiviral Res; 2004 Apr; 62(1):53-6. PubMed ID: 15026202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using ritonavir with indinavir in cases of virologic failure.
    TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
    Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
    Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection.
    Colebunders R; De Schacht C; Vanwolleghem T; Callens S
    Int J Infect Dis; 2004 Sep; 8(5):315-6. PubMed ID: 15325601
    [No Abstract]   [Full Text] [Related]  

  • 11. [Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].
    Moltó J; Clotet B
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():24-6. PubMed ID: 19572441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe dyslipidaemia after the addition of raltegravir to a lopinavir/ritonavir-containing regimen.
    Huesgen E; Burgos R; Goldstein DA; Max B; Jarrett OD
    Antivir Ther; 2012; 17(7):1385-8. PubMed ID: 22728657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating advanced HIV infection.
    Boffito M; Bonora S; Sinicco A; Raiteri R; Milia MG; Khoo SH; Hoggard PG; Back DJ; Di Perri G
    J Acquir Immune Defic Syndr; 2003 Nov; 34(3):344-5. PubMed ID: 14600582
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
    Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
    J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
    De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
    Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor].
    Ershov FI; Kas'ianova NV; Vasil'ev AN
    Antibiot Khimioter; 2002; 47(11):27-9. PubMed ID: 12698577
    [No Abstract]   [Full Text] [Related]  

  • 19. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
    Chang ES; Tetreault DD; Liu YT; Beall GN
    J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
    [No Abstract]   [Full Text] [Related]  

  • 20. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
    Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
    HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.